Walsh & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
Other funds holding ABBV
Walsh & Associates's ABBV Position: Q3 2026 in Review
Walsh & Associates reduced its AbbVie (ABBV) stake by 9.2% in Q3 2026, selling an estimated $19K and leaving 734 shares worth $192K. The position accounts for 0.15% of the portfolio, ranked #56.
Walsh & Associates first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. The position peaked at $203K in Q2 2026. 4,281 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.
- Walsh & Associates held 734 shares of AbbVie worth $192K as of Q3 2026.
- Walsh & Associates sold 74 AbbVie shares in Q3 2026, an estimated $19K.
- AbbVie made up 0.15% of Walsh & Associates's portfolio in Q3 2026, its #56 holding.
- Walsh & Associates first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
- Walsh & Associates's AbbVie position peaked at $203K in Q2 2026.
- 4,281 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.
Based on Walsh & Associates's 13F filing for Q3 2026, filed 9 Nov 2026.